Global Protamine Sulfate Injection Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Protamine Sulfate Injection Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Protamine Sulfate Injection, isotonic solution of protamine sulfate in Water for Injection, is a medication that is used to reverse the effects of heparin. It is specifically used in heparin overdose, in low molecular weight heparin overdose, and to reverse the effects of heparin during delivery and heart surgery.

Market Overview:

The latest research study on the global Protamine Sulfate Injection market finds that the global Protamine Sulfate Injection market reached a value of USD 80.31 million in 2022. It’s expected that the market will achieve USD 86.11 million by 2028, exhibiting a CAGR of 1.17% during the forecast period.

Supply chain and production stagnation

Due to the COVID-19 outbreak, many factories have closed. The production of protamine sulfate injection was also affected, and the market growth rate slowed down. The supply chain and downstream application industries are affected by the epidemic, which has also adversely affected the development of the protamine sulfate injection industry. Although COVID-19 currently has a long-term possibility, its subsequent impact depends on the development of the epidemic and related measures taken by the government.

Insufficient raw materials

Due to the impact of COVID-19, market transportation has been restricted and trade liquidity has weakened, resulting in a large shortage of fish sperm stocks. At the beginning of the epidemic, the market stock was not high, the overall supply was tight, and prices rose in various places. Due to insufficient raw materials, prices will rise. Overall, the current market for protamine sulfate injections will be in short supply and manufacturers are reluctant to conduct low-price transactions. Despite sluggish demand, overall trading downside is relatively limited.

Growing prevalence of heart surgeries

Protamine , the full name of protamine sulfate injection, is a kind of basic protein sulfate extracted from fresh mature sperm of fish. It is mainly used for bleeding caused by excessive heparin injection and is necessary for heart surgery. drug. Heart surgery patients undergo extracorporeal circulation during the operation. In order to ensure normal blood circulation, doctors will use heparin anticoagulant to prevent blood clotting outside the body. After the operation, if the blood still fails to coagulate, it will cause internal organs to ooze blood and endanger life. Protamine is the antidote to relieve anticoagulation to prevent massive bleeding. With the increasing development of medical technology, there are more and more cases of cardiac surgery, which brings many development opportunities to the protamine sulfate injection market.

Regulatory issues

Standard problems caused the protamine sulfate injection to fail the test, so production was discontinued in many places in the past few years. Another point is the pricing problem of protamine sulfate injection. The previous pricing mechanism has largely limited the profit margin of enterprises. The shortage of protamine sulfate injection still exists, and the situation is not optimistic. Many shortages involve products that are older, unpatented or difficult to formulate, and products that have strict shelf life and have few or only manufacturers. To improve the shortage of medicines, the government and the market must play a dual role, establish a scientific and reasonable prevention, and a long-term mechanism to deal with the shortage of protamine sulfate injection.

Region Overview:

In 2021, the share of the Protamine Sulfate Injection market in United States stood at 34.73%.

Company Overview:

Fresenius-kabi is one of the major players operating in the Protamine Sulfate Injection market, holding a share of 29.81% in 2022.

Fresenius-kabi

Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. Their products and services are used to help care for critically and chronically ill patients.

SHANGHAI PHARMA

Shanghai Pharmaceutical Group Co., Ltd. is a large national pharmaceutical industry group company headquartered in Shanghai. The company's business covers the entire pharmaceutical industry chain including drug research and development, manufacturing, distribution and retail. At the same time, it provides pharmaceutical value-added services and supply chain solutions for pharmaceutical companies, medical institutions and related units. The company is a rare pharmaceutical company in China that is in a leading position in both pharmaceutical manufacturing and sales.

Segmentation Overview:

Among different product types, 10 mg/mL SD Vial 5 mL segment is anticipated to contribute the largest market share in 2027.

Application Overview:

By application, the Heart Surgery segment occupied the biggest share from 2017 to 2022.

Heart Surgery

Neutralization of systemic anticoagulation with heparin in cardiac surgery with cardiopulmonary bypass requires protamine administration. If adequately dosed, protamine neutralizes heparin and reduces the risk of postoperative bleeding.

Delivery Surgery

Protamine sulfate injection is a medication that is used to reverse the effects of heparin. It is specifically used in heparin overdose, in low molecular weight heparin overdose, and to reverse the effects of heparin during delivery surgery. It is given by injection into a vein.

Key Companies in the global Protamine Sulfate Injection market covered in Chapter 3:

EIPICO
Fada Pharma
SHANGHAI PHARMA
Sanofi-Aventis
Galenika
UNITED BIOTECH
Fresenius-kabi

In Chapter 4 and Chapter 14.2, on the basis of types, the Protamine Sulfate Injection market from 2018 to 2029 is primarily split into:

10 mg/mL SD Vial 5 mL
10 mg/mL SD Vial 25 mL

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Protamine Sulfate Injection market from 2018 to 2029 covers:

Heart Surgery
Delivery Surgery

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)